Models for Measuring

The 2024 increase is the same as last year.The foundation’s annual survey of employer health benefits also found that only 18% of large employers are covering the GLP-1 weight loss drugs,

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

Apitegromab works by targeting a protein called myostatin that limits muscle growth and is designed to be used alongside existing spinal muscular atrophy (SMA) treatments.

In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.

The higher dose led to a more rapid decline in an important marker of neurodegeneration, according to a Biogen news release announcing the results.